Janux Therapeutics
2 known investors
Janux Therapeutics develops precision-engineered bispecific immunotherapies, including tumor-activated T cell engagers (TRACTr), designed to modulate T cells to treat cancer and autoimmune diseases. Its lead clinical program targets prostate cancer.
BiotechMedical Devices
Investors Β· 2
In the news
Janux Therapeutics (JANX) Narrows Quarterly Losses, Is The Premium Valuation Too Rich? - Simply Wall St Newssimplywall.st Β· Aug 2026
Janux Therapeutics Q2 2026 results and cash position | JANX Quarterly Report (10-Q)stocktitan.net Β· Aug 2026Frequently asked questions
- What does Janux Therapeutics do?
- Janux Therapeutics develops precision-engineered bispecific immunotherapies, including tumor-activated T cell engagers (TRACTr), designed to modulate T cells to treat cancer and autoimmune diseases. Its lead clinical program targets prostate cancer.
- Who are Janux Therapeutics's investors?
- Janux Therapeutics's investors include Avalon BioVentures, OrbiMed.